Insider

Boston Scientific approves new compensation plans and selects independent director

On November 17, 2026, the Boston Scientific board of directors approved the 2027 annual bonus plan and two long-term stock incentive programs for management. Simultaneously, the company announced that David S. Wichmann will become lead independent director effective January 1, 2027.

Verified against 3 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
white wooden desk on hallway inside building
Photo by Brandon Holmes on Unsplash

Key points

  • The board approved the 2027 annual bonus plan and two stock-based programs running through 2029.
  • The company retains the right to modify or suspend plans.

Compensation plan approvals and personnel changes

The board approved the 2027 annual bonus plan and two stock-based programs running through 2029. Additionally, David S. Wichmann will succeed Edward J. Ludwig as lead independent director, with Ludwig remaining on the board.

Annual bonus payouts depend on global sales, earnings per share, and quality goals. Long-term stock awards depend on total shareholder return compared to the S&P 500 Healthcare Index or sales growth against the financial plan.

Clawback policies and limitations

The company retains the right to modify or suspend plans. Compensation is subject to clawback policies, allowing the recovery of bonuses in cases of misconduct or material harm to the company. Upon termination of employment, stock award conditions change or result in forfeiture.

Original sources

  1. 8-K filing, November 17, 2026November 17, 2026SHA-256 of our archived copy 581e7d303975…
  2. 8-K EX-10.2 filing, November 17, 2026November 17, 2026SHA-256 of our archived copy d998a76404fd…
  3. 8-K EX-10.3 filing, November 17, 2026November 17, 2026SHA-256 of our archived copy d45f5058947a…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards